Q1 2026 Cytosorbents Corp Earnings Call Transcript

May 13, 2026 / 08:30 PM GMT

Release Date Price: $0.571 (-2.54%)

Transcript 10-Q8-K

Key Points

Positve

CytoSorbents Corp (CTSO) reported a 2% year-over-year revenue growth to $8.9 million, despite external headwinds.
The company's direct international business outside Germany grew by 13% year-over-year, indicating strong market penetration.
Gross margins remained robust at 69%, reflecting strategic production adjustments to improve working capital efficiency.
The company has made significant operational improvements, including a strategic workforce and cost reduction initiative, which reduced headcount by 10% and lowered operating expenses.
CytoSorbents Corp (CTSO) has a clear regulatory path forward for DrugSorb ATR, with potential FDA approval expanding the total addressable market significantly.

Negative

Sales in Germany declined year-over-year, although operational improvements are underway.
Distributor sales were flat, impacted by geopolitical disruptions in the Middle East due to the U.S.-Iran war.
The FDA has requested additional mechanistic data for DrugSorb ATR, potentially delaying the de novo application submission to late 2026 or early 2027.
Net loss increased to $5.1 million for the quarter, primarily due to non-cash impacts of foreign currency transactions.
The company's cash equivalents and restricted cash decreased to $6.4 million from $7.8 million at the end of the previous year.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CTSO.OQ - Cytosorbents Corp
Q1 2026 Cytosorbents Corp Earnings Call
May 13, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon, ladies and gentlemen, and welcome to the Side of Sorbent's First Quarter 2026 Earnings Conference Call.

At this time, all lines are in listen-only mode.

After the speaker's remarks, there will be a question-and-answer session. If you wish to ask a question during the Q&A session, please press *1.

As a reminder, this call is being recorded.

And now I would like to turn the conference over to Pete Mariani, Chief Financial Officer. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Kathleen, and good

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.